Pharmaceutical formulations for subcutaneous administration of furosemide
AssigneescPharmaceuticals Inc.
InventorsScott A. Michaels, Pieter Muntendam, Glenn R. Larsen
Life of this patent
Estimating the term…
Abstract
The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.
Claims20
A method of treating a human with or exhibiting the symptoms of edema, hypertension or heart failure, the method comprising:
- administering subcutaneously to a human a liquid pharmaceutical formulation, wherein the liquid pharmaceutical formulation comprises:
- furosemide as the sole therapeutically active agent in the liquid pharmaceutical formulation, wherein the amount of furosemide in the liquid pharmaceutical formulation is about 5 mg/mL or greater;
- and
- tris(hydroxymethyl)aminomethane, wherein the concentration of tris(hydroxymethyl)aminomethane in the liquid pharmaceutical formulation is in a range of about 50 mM to about 500 mM;
- wherein the liquid pharmaceutical formulation is isosmotic and has a pH between about 7 to about 8.5, and the molar ratio of tris(hydroxymethyl)aminomethane to furosemide is greater than about 1.5.
A method of treating a human with or exhibiting the symptoms of edema, hypertension or heart failure, the method comprising:
- administering subcutaneously to a human using a patch device a liquid pharmaceutical formulation comprising:
- furosemide as the sole therapeutically active agent in the liquid pharmaceutical formulation, wherein the amount of furosemide in the liquid pharmaceutical formulation is about 15 mg/mL or greater;
- and
- tris(hydroxymethyl)aminomethane, wherein the concentration of tris(hydroxymethyl)aminomethane in the liquid pharmaceutical formulation is in a range of about 50 mM to about 500 mM;
- wherein the liquid pharmaceutical formulation is isosmotic and has a pH between about 7.2 to about 8, and the molar ratio of tris(hydroxymethyl)aminomethane to furosemide is greater than or equal to 1.5.
Dependencies are inferred from the claim text.